High methylglyoxal linked to adverse CV profile in Type 2 diabetics
MedWire News: Elevated methylglyoxal levels predict increased carotid intima-media thickness (IMT) and increased blood pressure (BP) in patients with Type 2 diabetes, report researchers.
Urinary albumin excretion rate (ACR) and estimated glomerular filtration rate (eGFR) were not affected by a high methylglyoxal concentration, however.
Results from animal studies have suggested that methylglyoxal, a toxic α-oxoaldehyde, may be involved in the progression of macro- and microangiopathy in diabetes.
To investigate further, Susumu Ogawa (Tohoko University, Sendai, Japan) and colleagues measured levels of methylglyoxal and another α-oxoaldehyde 3-deoxyglucosone (DG) in 50 Type 2 diabetics, aged 61.3 years on average.
They then assessed correlations between baseline levels of the two aldehydes and change in carotid IMT, systolic BP, urinary ACR, pulse wave velocity (PWV), and eGFR over 5 years of follow-up.
They found that carotid IMT, PWV, systolic BP, and urinary ACR significantly increased and eGFR significantly decreased in the participants over the follow-up period.
Baseline methylglyoxal level significantly positively correlated with the changes in carotid IMT, PWV, and systolic BP, but not with changes in urinary ACR and eGFR.
Conversely, baseline DG concentration positively correlated only with changes in urinary ACR level, but not with changes in the other measures.
"This study provides for the first time evidence that methylglyoxal is a predictor in Type 2 diabetes mellitus of intima-media thickening, of vascular stiffening, and of elevation of systolic BP, suggesting its clinical usefulness as a biomarker for diabetic macroangiopathy," conclude the authors in the journal Hypertension.
"Medical agents interfering with α-oxoaldehydes, such as methylglyoxal, or decreasing their production may have potential therapeutic benefits for diabetic angiopathies," they suggest.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Helen Albert